Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ablynx NV issues pipeline update


Wednesday, 14 May 2014 01:00am EDT 

Ablynx NV:Says in order to support the start of first-in-infant study during Q4 2014 with the anti-RSV Nanobody, the Company carried out additional pre-clinical study in neonatal lambs together with two additional Phase I studies focusing on safety and pharmacokinetics (PK).Neonatal lamb study successfully demonstrated that daily inhalation of ALX-0171 resulted in reduction of viral titres and lung inflammation, and was effective in alleviating various clinical signs and symptoms.New Phase I results were announced on May 6.Phase I safety study demonstrated that in patients with hyper-reactive airways, if bronchoconstriction occurred after inhalation of ALX-0171, then it could be reversed with standard bronchodilators.Phase I PK study in healthy volunteers showed again that ALX-0171 was well tolerated and that once-daily administration resulted in rapid attainment of clinically relevant Nanobody levels in lung.Says after completing pre-clinical studies with anti-IgE Nanobody, ALX-0962, for use in severe allergic asthma, Ablynx has decided not to move forward with this program into Phase I studies because of insufficient differentiation from competition.Says in May, Boehringer Ingelheim (B.I.) terminated a Phase I study initiated in Oct. 2013, with a Nanobody designed to treat Alzheimer`s disease, prior to completion of volunteer recruitment.Study was stopped according to protocol and B.I. is now reviewing program. 

Company Quote

8.77
0.09 +1.04%
27 Aug 2014